Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366332477> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4366332477 endingPage "7" @default.
- W4366332477 startingPage "1" @default.
- W4366332477 abstract "Abstract OBJECTIVE To report on survival rates and risk factors in dogs with immune-mediated hemolytic anemia (IMHA) and immune-mediated thrombocytopenia (ITP) treated with human IV immunoglobulin (hIVIG; Privigen). We hypothesized that hIVIG could be used as a salvage treatment to improve survival and reduce the requirement for ongoing blood transfusion therapy in IMHA and ITP patients. ANIMALS 52 client-owned dogs with IMHA or ITP were included, comprising 31 females (28 spayed and 3 entire) and 21 males (19 castrated and 2 entire). Miniature Schnauzers were the most common breed (5), with a further 24 different breeds identified. PROCEDURES A retrospective cohort study was conducted between January 2006 and January 2022 that assessed the survival rates, risk factors, and need for ongoing transfusion in dogs with IMHA and ITP treated with hIVIG compared with those not receiving hIVIG. RESULTS Of 36 dogs that did not receive hIVIG, 29 (80%) survived and 7 (24%) died, and of 16 dogs administered hIVIG, 11 (69%) survived and 5 (31%) died ( P = .56). No effect of PCV at admission or age on the risk of death was detected (OR, 1.00; 95% CI, 0.94 to 1.08; P = .89; and OR, 1.10; 95% CI, 0.85 to 1.47; P = .47, respectively). CLINICAL RELEVANCE This was the largest study to date of dogs with hematological immune-mediated disease treated with hIVIG. There was no difference in survival rates for dogs that received hIVIG versus those treated with standard immunosuppression. The benefit of hIVIG as a salvage treatment appears limited." @default.
- W4366332477 created "2023-04-20" @default.
- W4366332477 creator A5014654181 @default.
- W4366332477 creator A5049749572 @default.
- W4366332477 date "2023-04-18" @default.
- W4366332477 modified "2023-10-01" @default.
- W4366332477 title "Human intravenous immunoglobulin use for hematological immune-mediated disease in dogs" @default.
- W4366332477 doi "https://doi.org/10.2460/javma.23.01.0043" @default.
- W4366332477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37072115" @default.
- W4366332477 hasPublicationYear "2023" @default.
- W4366332477 type Work @default.
- W4366332477 citedByCount "1" @default.
- W4366332477 countsByYear W43663324772023 @default.
- W4366332477 crossrefType "journal-article" @default.
- W4366332477 hasAuthorship W4366332477A5014654181 @default.
- W4366332477 hasAuthorship W4366332477A5049749572 @default.
- W4366332477 hasBestOaLocation W43663324771 @default.
- W4366332477 hasConcept C126322002 @default.
- W4366332477 hasConcept C159654299 @default.
- W4366332477 hasConcept C167135981 @default.
- W4366332477 hasConcept C197934379 @default.
- W4366332477 hasConcept C203014093 @default.
- W4366332477 hasConcept C2776482104 @default.
- W4366332477 hasConcept C2778248108 @default.
- W4366332477 hasConcept C2780014101 @default.
- W4366332477 hasConcept C2780252810 @default.
- W4366332477 hasConcept C54355233 @default.
- W4366332477 hasConcept C71924100 @default.
- W4366332477 hasConcept C72563966 @default.
- W4366332477 hasConcept C86803240 @default.
- W4366332477 hasConcept C8891405 @default.
- W4366332477 hasConceptScore W4366332477C126322002 @default.
- W4366332477 hasConceptScore W4366332477C159654299 @default.
- W4366332477 hasConceptScore W4366332477C167135981 @default.
- W4366332477 hasConceptScore W4366332477C197934379 @default.
- W4366332477 hasConceptScore W4366332477C203014093 @default.
- W4366332477 hasConceptScore W4366332477C2776482104 @default.
- W4366332477 hasConceptScore W4366332477C2778248108 @default.
- W4366332477 hasConceptScore W4366332477C2780014101 @default.
- W4366332477 hasConceptScore W4366332477C2780252810 @default.
- W4366332477 hasConceptScore W4366332477C54355233 @default.
- W4366332477 hasConceptScore W4366332477C71924100 @default.
- W4366332477 hasConceptScore W4366332477C72563966 @default.
- W4366332477 hasConceptScore W4366332477C86803240 @default.
- W4366332477 hasConceptScore W4366332477C8891405 @default.
- W4366332477 hasLocation W43663324771 @default.
- W4366332477 hasLocation W43663324772 @default.
- W4366332477 hasOpenAccess W4366332477 @default.
- W4366332477 hasPrimaryLocation W43663324771 @default.
- W4366332477 hasRelatedWork W150249736 @default.
- W4366332477 hasRelatedWork W2246192078 @default.
- W4366332477 hasRelatedWork W2315085516 @default.
- W4366332477 hasRelatedWork W2365865005 @default.
- W4366332477 hasRelatedWork W2392337508 @default.
- W4366332477 hasRelatedWork W2603773853 @default.
- W4366332477 hasRelatedWork W3208090289 @default.
- W4366332477 hasRelatedWork W3210359220 @default.
- W4366332477 hasRelatedWork W3213024368 @default.
- W4366332477 hasRelatedWork W4200303112 @default.
- W4366332477 isParatext "false" @default.
- W4366332477 isRetracted "false" @default.
- W4366332477 workType "article" @default.